January 6-7, 2022 webconference

The Longwood Healthcare Leaders meeting, centered on Stanford/San Francisco via webconference on Thursday, January 6 - Friday, January 7, 2022 prior to the JP Morgan Healthcare Conference, brings together leading biopharma CEOs, heads of R&D, top academic researchers, and healthcare investors for an off-the-record forum focused on accelerating the translation of discoveries into medicines to help patients.

Speakers include Stanford University President Marc Tessier-Lavigne, Stanford School of Medicine Dean Lloyd Minor, AbbVie Chief Strategy Officer Henry Gosebruch, Novartis Institute for BioMedical Research President Jay Bradner, SeaGen CEO Clay Siegall, Daiichi Sankyo Executive Chair, head of R&D and President Glenn Gormley, Nestle Health Science CEO Greg Behar, Bayer Global Head of BD&L Marianne De Backer, Vir Bio CMO Phil Pang, Alladapt CEO Ashley Dombkowski, Takeda Neuroscience head Beth Shafer, Genocea CEO Chip Clark, among others. Substantial donations enabled by these meetings benefit Life Science Cares, The Boston Foundation, BSO, Harvard Medical School, MIT, and other charities.

Supporters

We are grateful to the following organizations for their support of this meeting. To learn more about getting involved contact susan@longwoodfund.com

BenchSci's vision is to help scientists bring novel medicine to patients 50% faster by 2025. We do this by empowering scientists to run more successful experiments with the world's most advanced, intuitive biomedical artificial intelligence software platform, thereby avoiding delays that slow the progress of medicine to clinical trials. BenchSci is an indispensable tool for more than 41,000 scientists that accelerates research at 15 top 20 pharmaceutical companies and over 4,300 leading academic centers.

LONGWOOD HEALTHCARE LEADERS WINTER WEBCONFERENCE | DRAFT AGENDA | JANUARY 6-7, 2022

– all times Pacific Standard –

THURSDAY, JANUARY 6, 2022

7:00 – 7:30 | LONGWOOD FUND INTRODUCTION

7:30 – 8:00 | NEWCO TO ESTABLISHED: BUILDING A BIOTECH

Mark McKenna, CEO, Prometheus Bio

8:00 – 8:30 | R&D COLLABORATION

8:30 – 8:50 | FIRESIDE CHAT: STANFORD MEDICINE
Marc Tessier-Lavigne, President, Stanford; Lloyd Minor, Dean, Stanford Medicine

8:50 – 9:20 | BULDING GLOBAL BIOPHARMAS

9:20 – 9:50 | EXPEDITING RESEARCH FOR TREATMENTS AND CURES

George Demetri, Executive Director, Clinical & Translational Research, Ludwig Institute for Cancer Research, Dana-Farber Cancer Institute

9:50 – 10:20 | SOURCING AND IDENTIFYING NOVEL TECHNOLOGY

Pearl Huang, CEO, Cygnal Therapeutics; Beth Shafer, Head, Neuroscience, Drug Discovery Sciences, & Externalization BD, Takeda

10:20 – 10:40 | FIRESIDE CHAT
Jay Bradner, President, Novartis Institutes for BioMedical Research

10:40 – 11:10 | INNOVATION IN CELL THERAPY
Jak Knowles, CEO, Affini-T

11:10 – 11:40 | CULTIVATING AN ECOSYSTEM OF PARTNERS

Greg Behar, CEO, Nestle Health Science; Axel Hoos, CEO, Scorpion Therapeutics

11:40 – 12:00 | FIRESIDE CHAT

12:00 – 12:30 | HOW M&A SPURS INNOVATION

Henry Ji, CEO, Sorrento Therapeutics; Elizabeth Mily, EVP, Strategy & BD, Bristol Myers Squibb

12:30 – 1:00 | SCIENTIFIC INNOVATION: LAUNCHING COMPANIES FROM ACADEMIA

Ashley Dombkowski, CEO, Alladapt

1:00 – 1:30 | ADVANCING PLATFORM TECHNOLOGIES

Sarah Boyce, CEO, Avidity Bio; Steve Potts, CEO, OncoMyx Therapeutics; Carlo Russo, CMO & Head of Development, Genenta

1:30 – 1:50 | FIRESIDE CHAT

Henry Gosebruch, Chief Strategy Officer, AbbVie

1:50 – 2:20 | DRUG APPROVALS: INSIGHTS, OUTLOOK, AND COMMITMENT TO PATIENTS

Clay Siegall, CEO, SeaGen

2:20 – 2:50 | MAKING A BIG IMPACT WITH LIMITED RESOURCES

Chip Clark, CEO, Genocea; Carol Nacy, CEO, Sequella; Neil Weir, CEO, Sitryx

2:50 – 3:20 | ACCELERATING DRUG DEVELOPMENT

Phil Pang, CMO, Vir Bio

3:20 – 3:50 | MAKING SMART INVESTMENTS

3:50 – 4:00 | LONGWOOD FUND SUMMARY

FRIDAY, JANUARY 7, 2022

– all times Pacific Standard –

7:00 – 7:30 | LONGWOOD FUND INTRODUCTION

7:30 – 8:00 | HARNESSING BIOMEDICAL INNOVATION

8:00 – 8:20 | MODERATED KEYNOTE

8:20 – 8:50 | HEALTH SYSTEMS IN A NEW ERA

8:50 – 9:20 | BIG BIOPHARMA R&D

Philip Larsen, Global Head of Research and Early Development, Bayer

9:20 – 9:50 | SPOTLIGHT: STANFORD INNOVATION

Alyce Adams, Stanford Medicine Innovation Professor, Stanford; Carolyn Bertozzi, Baker Family Director of Stanford ChEM-H, Stanford; Catherine Blish, Professor of Medicine, Infectious Diseases, Stanford; Bali Pulendran, Professor of Microbiology and Immunology, Stanford

9:50 – 10:20 | NOVEL THERAPEUTIC MODALITIES

10:20 – 10:40 | FIRESIDE CHAT

10:40 – 11:10 | DESIGNING THE DEAL

Marianne De Backer, EVP, Global Head, BD&L, Bayer; Brad Posek, CBO, Constellation Pharmaceuticals

11:10 – 11:40 | DEVELOPING A WORLD-CLASS BOARD

Adam Bruce, Founder & Executive Board Member, TikoMed

11:40 – 12:00 | FIRESIDE CHAT

Mathai Mammen, Global Head, R&D, Janssen Pharmaceuticals

12:00 – 12:20 | CLINICAL TRIAL DIVERSITY

12:30 – 1:00 | FINANCING INNOVATION

Peter Bisgaard, Managing Director, Nan Fung Life Sciences

1:00 – 1:20 | FIRESIDE CHAT

1:20 – 1:50 | R&D TRANSFORMATION

Glenn Gormley, Executive Chair, President, Head R&D, Daiichi Sankyo

1:50 – 2:20 | THE NEXT WAVE OF FINANCINGS: IPOS, REVERSE MERGERS, SPACS

Brian Silver, CFO, TScan Therapeutics

2:20 – 2:50 | FIRESIDE CHAT

2:50 – 3:20 | INNOVATIVE PARTNERSHIPS

3:20 – 3:40 | NOVEL APPROACHES TO DUG DISCOVERY
Cigall Kadoch, Institute Member and Epigenomics Program Co-Director, Broad Institute of MIT and Harvard

3:40 – 4:00 | LONGWOOD FUND SUMMARY